https://www.selleckchem.com/pr....oducts/bezafibrate.h
sensitivity of 39% and an AUC of 0.77. The RV/TLC ratio combined to FeNO may be of interest to predict significant methacholine bronchial hyperresponsiveness. In recent years, major developments have occurred in severe asthma management. Different asthma phenotypes and subgroups have been identified and new treatment options have become available. A total of five monoclonal antibodies are currently approved in severe asthma treatment omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab. These drugs have been shown to redu
Beğen
Yorum Yap
Paylaş
